INmune Bio
INMB
83 hedge funds and large institutions have $7.09M invested in INmune Bio in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 21 closing their positions.
158% more call options, than puts
Call options by funds: $124K | Put options by funds: $48K
18% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 22
16% more capital invested
Capital invested by funds: $6.09M → $7.09M (+$1M)
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
1% more funds holding
Funds holding: 82 → 83 (+1)
3.88% less ownership
Funds ownership: 20.23% → 16.35% (-3.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$542K |
| 2 |
Millennium Management
New York
|
+$221K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$147K |
| 4 |
HF
HRT Financial
New York
|
+$117K |
| 5 |
Jane Street
New York
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.22M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$422K |
| 3 |
State Street
Boston,
Massachusetts
|
-$273K |
| 4 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$254K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$203K |
INMB Hedge Fund Activity: Q2 2026 in Review
83 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q2 2026, worth a combined $7.09M — up 16% from $6.09M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new INMB positions and 21 closed out — a net gain of 3 holders — while 26 added to existing stakes and 22 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $542K. The largest seller was BlackRock, cutting an estimated $1.22M.
- 83 institutional investors held INmune Bio (INMB) as of Q2 2026, up from 82 in Q1 2026.
- Funds reported $7.09M of INmune Bio stock for Q2 2026, up 16% quarter-over-quarter.
- 24 funds opened new INmune Bio positions in Q2 2026 and 21 closed out, a net change of +3 holders.
- The largest INmune Bio buyer in Q2 2026 was AQR Capital Management, an estimated $542K added.
- The largest INmune Bio seller in Q2 2026 was BlackRock, an estimated $1.22M sold.
Based on aggregated 13F filings for Q2 2026.